ChinJViralDisJanuary2012Vol.2No.1 HBV HBV 3. : HBV [9] (FDA) HBV HBV HBV HBV -HBs [5] HBV HBV B ( HIV ) ( (AFP) HCC [6] HBV 1. : HBV HBV (

HTML
DOWNLOAD

Μέγεθος: px

Εμφάνιση ξεκινά από τη σελίδα:

Download "ChinJViralDisJanuary2012Vol.2No.1 HBV HBV 3. : HBV [9] (FDA) HBV HBV HBV HBV -HBs [5] HBV HBV B ( HIV ) ( (AFP) HCC [6] HBV 1. : HBV HBV ("

Ωρίων Μπλέτσας
8 χρόνια πριν
Προβολές:

1 ChinJViralDisJanuary2012Vol.2No.1 11 : ; ; ; :R :C : (2012) TechnicalguideforadulthepatitisBimmunizationinChina Chinese Prevention Medicine AsociationNationalImmunization ProgramChineseCenterfor DiseaseControland Prevention Corresponding author:liang Xiao-fengChineseCenterfor DiseaseControl and PreventionBeijing100050China. liangxf@hotmail.com Keywords:HepatitisB;Adult;Immunologicaldefense;Technicalguide ( ) (HBV) HBV HBV 1992 HBV <5 (HBsAg) HBV ; 30%~50% ( 5) HBV [2] HBV 6 HBV HBV [3] () 5 [4] 10% (HIV HBV ) HBV HBV DNA DNA [2-3] 25% HBV 42nm 3.2kb HBV DNA HBV (HCC);HBV HCC 10 5% HBV HBV HCC 100~300 [3] 4 [1] () 3~6 : liangxf@hotmail.com HBV 4 HBV (5%) HBV HBV 90% 25%~30%5%~ 1% 10d

2 ChinJViralDisJanuary2012Vol.2No.1 HBV HBV 3. : HBV [9] (FDA) HBV HBV HBV HBV -HBs [5] HBV HBV B ( HIV ) ( (AFP) HCC [6] HBV 1. : HBV HBV ( 8%) 30~40 HCC ; (2%~8%) HBV HBV ; (<2%)20~29 [10] 2005 [3] ~45 79% (45~160)d 2 ; ( ) 5%16% HBV 40%~50% HBsAg HBV e (HBeAg) HBV [311] 2. :HBV [12] ( ) (MSM) HBV (1) : 40%~50% HBsAg [3811] HBV HBV HBV [3] HBsAgHBeAg () (2) :HBV [11] 70%~90% () HBV [8] HBV (2) : HBV ( ) (3) : HBsAg HBV ) ( ) HBV HBV 4. HBV : [11] HBsAg (1) : HBV (70%MSM 5 ) HBV HBV HBV (3) : HBV HBV HB-

3 ChinJViralDisJanuary2012Vol.2No.1 13 sag HBV HBV (4): (WHO) HBV (IVDAs) HIV HIV HBV 45% 24%43% [17] HBV HIV 6% ~15% MSM 9% ~17%IDUs 7%~10% 4%~6% [18] <5 (6) : HBsAg 0.96% ( 90%) [21-22] HBV HBV 5 ~ 14 HBsAg HBV 2.42%15~59 HBsAg HBV 6 HBV 2%~5% [11] 15~59 -HBs (7) : 47.38% [21] HBV 3. : HBV 2009 HBV 6 [2023] HBsAg ; HBV HBV (8) : 30 HBV 50% HCC 1. : HBV % ;2002 [13] 21 ; [19-20] (IDUs) HBV 24h 1 1 [14-15] 26 3 (CDC) HBV 16% [11] 6 HBV HBV IDUs64% (50%~ [16] %) (<15 ) <15 HBsAg (5)HIV : HIV HBsAg HBV HBV 22~29 MSM HIV 2. : ~59 HBsAg 7.18% % 26.36% [21] 8.57% HBsAg HBV 5%

4 ChinJViralDisJanuary2012Vol.2No.1 5%~20% [26] HBV 3 (1) / : ACIP 10~ μg [211] WHO CDC ( 20 ) [24] 95 20μg : [27-29] / 18 20μg : (1) : MSM HBsAg (2) : ( ) (2010 ) (3) : ( ) ( IDUs HBsAg ) HBV ( )IDUs (4) : HBV μg HIV μg 2. : 3 4. : (3~6 ) HBIG 3 HBV HBV 3. : [911] (2) : WHO CDC (HBIG) HBIG 120μg HBIG200~400IU (ACIP) [25] 5. : HBV (-HBs< 10mIU/ml)

5 ChinJViralDisJanuary2012Vol.2No.1 15 : ~2 -HBs 1 60μg 6.: ; Recomm Rep (RR-16):1-33E1-E4. : ; ( amongyoungmenwhohavesexwithmen [J].AmJPublic ): [13] Health (6): HauriAMArmstrongGLHutinYJ.Theglobalburdenof disease atributable to contaminated injections given in ; ( ): [1] Liaw YF.NaturalhistoryofchronichepatitisBvirusinfec- tionandlong-termoutcomeundertreatment [J].LiverInt Suppl1: [2] MastEEMargolisHSFioreAEetal.Acomprehensive immunizationstrategytoeliminatetransmissionofhepatitis BvirusinfectionintheUnitedStates:recommendationsof theadvisorycommiteeonimmunizationpractices(acip) part1:immunizationofinfantschildrenandadolescents [J].MMWR Recomm Rep (RR-16):1-31. [3] ShepardCWSimardEPFineliLetal.HepatitisBvirus infection:epidemiologyandvaccination [J].EpidemiolRev (2): [4] LaiCLRatziuVYuen MFetal.ViralhepatitisB [J]. Lancet (9401): [5] LokASMcmahonBJ.ChronichepatitisB:update2009 [J]. Hepatology (3): [6] BruixJSherman M.Managementofhepatocelularcarcino- ma [J].Hepatology (5): ChineseSocietyofHepatologyandChineseSocietyofInfec- tiousdiseaseschinese MedicalAssociation.Theguideline ofpreventionandtreatmentforchronichepatitisb (2010 version)[j].zhonghua Ganzang bing Zazhi (1):13-24.(inChinese) 11-01].htp:// atitisbwhocdscsrlyo20022.pdf. [10] YeDQ.Epidemiology [M].6thed.Beijing:People smedi- calpublishinghouse2006.(inchinese). [M].6 : [20] CuiFQGongXHChenYSetal.ChinesehepatitisBim-. munizationstrategiesandfeasibilityofexpandingthevacci- (2010 )[J]. nationtochildrenandhighriskpopulationamongadult[j] (1): ZhongguoYimiaoHeMianyi (6): (in [8] Alter MJ.EpidemiologyandpreventionofhepatitisB [J]. SeminLiverDis (1): Chinese). [9] World Health Organization.HepatitisB [EB/OL].[2011- [J] [11] MastEEWeinbaum CMFioreAEetal.Acomprehen- siveimmunizationstrategytoeliminatetransmissionofhep- tionsoftheadvisorycommiteeonimmunizationpractices (ACIP)Part I:immunization of adults [J].MMWR [12] MacKelarDAValeroyLASecuraGMetal.Twodecades aftervaccinelicense:hepatitisbimmunizationandinfection healthcaresetings [J].IntJSTD AIDS (1): [14] HouJLiuZGuFetal.Epidemiologyandpreventionof hepatitisbvirusinfection [J].IntJMedSci20052 (1): atitisbvirusinfectioninthe UnitedStates:recommenda- [15] BialekSRBowerWAMotram Ketal.Riskfactorsfor hepatitisbinanoutbreakofhepatitisbanddamonginjec- tiondrugusers [J].JUrban Health (3): mentin6 UScities [J].Am JPublic Health (3): [16] MurrilCSWeeksHCastrucciBCetal.Age-specificse- roprevalenceofhivhepatitisbvirusandhepatitiscvirus infectionamonginjectiondrugusersadmitedtodrugtreat- [17] TienPCKovacsABacchetiPetal.Associationbetween syphilisantibodiestoherpessimplexvirustype2andrec- reationaldrug useand hepatitis B virusinfectioninthe Women sinteragency HIV Study [J].ClinInfect Dis (9): [18] AlterMJ.Epidemiologyofviralhepatitisand HIVco-infection [J].JHepatol (1Suppl):S6-S9. [19] ChineseSocietyofHepatologyandChineseSocietyofInfec- tiousdiseaseschinese MedicalAssociation.Theguideline ofprevention andtreatmentforchronic hepatitis B [J]. ZhonghuaGanzangbingZazhi (12): (in Chinese). [J] (12):

6 檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾檾 ChinJViralDisJanuary2012Vol.2No (6): [21] htp:// html. [22] CuiFQ.EpidemiologicalinvestigationofviralhepatitisBin Chinesepopulation:hepatitis B virusvaccination hasre- ducedhepatitisbvirusinfection [J].ZhongguoYimiao He Mianyi (4): (inChinese). [27] ChiaramonteMMajoriSNgatchuTetal.Twodiferent [J]. dosagesofyeastderivedrecombinanthepatitisbvaccines:a (4): comparisonofimmunogenicity [J].Vaccine (2): [23] ZhuangH.ProgressinepidemiologyofhepatitisB[J].Guowaiy- ixue Liuxingbingxue Chuanranbingxue Fence (3): (inChinese). [J]. 2): (3): [29] ul-haqnhasnainssumarmetal.immunogenicityof [24] GuanZQDongZHWangQHetal.Costofchronichep- 10and20μghepatitisBvaccineinatwo-doseschedule[J]. atitisbinfectioninchina [J].JClinGastroenterol2004 Vaccine (23): (10Suppl3):S175-S178. [25] TheImmunizationPracticesAdvisoryCommitee(ACIP). Recommedationforprotectionagainstviralhepatitis [J]. MMWR (22): [26] LiaoXYZhuangH.HepatitisBvaccinationwithoutscreen- ingissafe [J].Zhongguo Yufang YixueZazhi (10): (inChinese). [J] (10): [28] AssadSFrancisA.Overadecadeofexperiencewithayeastre- combinanthepatitisbvaccine [J].Vaccine (1/ : : GB/T : : :84062 GB [1987]93147 CN /22 HP B12

Σχετικά έγγραφα

ΚΑΛΛΙΟΠΗ ΖΑΧΟΥ ΠΑΘΟΛΟΓΟΣ. Παθολογική Κλινική & Ερευνητικό Εργαστήριο Παν/μίου Θεσσαλίας

ΚΑΛΛΙΟΠΗ ΖΑΧΟΥ ΠΑΘΟΛΟΓΟΣ. Παθολογική Κλινική & Ερευνητικό Εργαστήριο Παν/μίου Θεσσαλίας ΚΑΛΛΙΟΠΗ ΖΑΧΟΥ ΠΑΘΟΛΟΓΟΣ Παθολογική Κλινική & Ερευνητικό Εργαστήριο Παν/μίου Θεσσαλίας Fattovich, J Hepatol 2008 Ετήσια επίπτωση ρήξης αντιρρόπησης 3-4% Ετήσια επίπτωση HKK 2-4% Επιβίωση 5ετής σε αντιρροπούμενη